Comparative pre-clinical and clinical experience with oral polio vaccine produced on MRC-5 cells or on primary monkey kidney cells

Príkazský, V.; Leroux‐Roels, Geert; Damme, Pierre Van; Safary, Assad; Colau, Brigitte; Duchêne, Michel

doi:10.1016/j.vaccine.2005.04.002

Cited by 4 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Table summarizes the evidence from seroconversion studies for OPV identified in our review of the literature . Numerous studies from countries of all income levels around the world demonstrate the ability of OPV to induce seroconversion, although they also reveal important variability and generally lower rates in less temperate settings.…”

Section: Resultsmentioning

confidence: 99%

Preeradication Vaccine Policy Options for Poliovirus Infection and Disease Control

Thompson

Pallansch

Tebbens³

et al. 2013

Risk Analysis

View full text Add to dashboard Cite

With the circulation of wild poliovirus (WPV) types 1 and 3 continuing more than a decade after the original goal of eradicating all three types of WPVs by 2000, policymakers consider many immunization options as they strive to stop transmission in the remaining endemic and outbreak areas and prevent reintroductions of live polioviruses into nonendemic areas. While polio vaccination choices may appear simple, our analysis of current options shows remarkable complexity. We offer important context for current and future polio vaccine decisions and policy analyses by developing decision trees that clearly identify potential options currently used by countries as they evaluate national polio vaccine choices. Based on a comprehensive review of the literature we (1) identify the current vaccination options that national health leaders consider for polio vaccination, (2) characterize current practices and factors that appear to influence national and international choices, and (3) assess the evidence of vaccine effectiveness considering sources of variability between countries and uncertainties associated with limitations of the data. With low numbers of cases occurring globally, the management of polio risks might seem like a relatively low priority, but stopping live poliovirus circulation requires making proactive and intentional choices to manage population immunity in the remaining endemic areas and to prevent reestablishment in nonendemic areas. Our analysis shows remarkable variability in the current national polio vaccine product choices and schedules, with combination vaccine options containing inactivated poliovirus vaccine and different formulations of oral poliovirus vaccine making choices increasingly difficult for national health leaders.

show abstract

Section: Resultsmentioning

confidence: 99%

Preeradication Vaccine Policy Options for Poliovirus Infection and Disease Control

Thompson

Pallansch

Tebbens³

et al. 2013

Risk Analysis

View full text Add to dashboard Cite

show abstract

“…To maintain a polio-free Iran, routine and mass vaccination need to be continued. Past [Jacobs, 1970;Mirchamsy et al, 1981;Mirchamsy and Shafyi, 1984;Dunn et al, 1990;Prikazsky et al, 2005] and present studies of OPV produced in MRC-5 cells have confirmed the safety and efficacy of this vaccine.…”

Section: Discussionmentioning

confidence: 53%

“…Although the previous studies based on monkey neurovirulence test (MNVT), MAPREC (analysis by PCR and restriction enzyme cleavage), and clinical trials [Mirchamsy et al, 1981;Mirchamsy and Shafyi, 1984;Prikazsky et al, 2005] have shown that OPV vaccines produced in MRC-5 are safe and effective, the complete genome sequence of this vaccine remains to be identified. The complete genome sequence of vaccine seeds, OPV3 propagated in some other cells, several OPV-like and Sabin vaccine-derived polioviruses (VDPVs) have been determined [Stanway et al, 1983Almond et al, 1984Almond et al, , 1987Cann et al, 1984;Toyoda et al, 1984;Rezapkin et al, 1995;Chezzi et al, 1998;Blomqvist et al, 2004;Dedepsidis et al, 2008;Shahmahmoodi et al, 2008].…”

Section: Introductionmentioning

confidence: 99%

Phenotypic and genomic analysis of serotype 3 sabin poliovirus vaccine produced in MRC‐5 Cell substrate

Alirezaie

Taqavian

Aghaiypour

et al. 2011

Journal of Medical Virology

View full text Add to dashboard Cite

The cell substrate has a pivotal role in live virus vaccines production. It is necessary to evaluate the effects of the cell substrate on the properties of the propagated viruses, especially in the case of viruses which are unstable genetically such as polioviruses, by monitoring the molecular and phenotypical characteristics of harvested viruses. To investigate the presence/absence of mutation(s), the near full-length genomic sequence of different harvests of the type 3 Sabin strain of poliovirus propagated in MRC-5 cells were determined. The sequences were compared with genomic sequences of different virus seeds, vaccines, and OPV-like isolates. Nearly complete genomic sequencing results, however, revealed no detectable mutations throughout the genome RNA-plaque purified (RSO)-derived monopool of type 3 OPVs manufactured in MRC-5. Thirty-six years of experience in OPV production, trend analysis, and vaccine surveillance also suggest that: (i) different monopools of serotype 3 OPV produced in MRC-5 retained their phenotypic characteristics (temperature sensitivity and neuroattenuation), (ii) MRC-5 cells support the production of acceptable virus yields, (iii) OPV replicated in the MRC-5 cell substrate is a highly efficient and safe vaccine. These results confirm previous reports that MRC-5 is a desirable cell substrate for the production of OPV.

show abstract

“…In addition, it is well tolerated and suitable for the production of various viral vaccines. 16 MRC-5 cells have been used by many vaccine manufacturers worldwide to develop various vaccines. 17,18 Regarding medical expenses, foreign HDCV in developed countries such as Europe and America cost US$1800 for the entire post-exposure prophylaxis process.…”

Section: Discussionmentioning

confidence: 99%

Pre-marketing immunogenicity and safety of a lyophilized purified human diploid cell rabies vaccine produced from microcarrier cultures: a randomized clinical trial

Zhou

Cai³

et al. 2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

Comparative pre-clinical and clinical experience with oral polio vaccine produced on MRC-5 cells or on primary monkey kidney cells

Cited by 4 publications

References 18 publications

Preeradication Vaccine Policy Options for Poliovirus Infection and Disease Control

Preeradication Vaccine Policy Options for Poliovirus Infection and Disease Control

Phenotypic and genomic analysis of serotype 3 sabin poliovirus vaccine produced in MRC‐5 Cell substrate

Pre-marketing immunogenicity and safety of a lyophilized purified human diploid cell rabies vaccine produced from microcarrier cultures: a randomized clinical trial

Contact Info

Product

Resources

About